5e5 of anti-BCMA CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human BCMA, His Tag (Cat. No. BCA-HA2H4) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). APC signal was used to evaluate the binding activity (QC tested).
Anti-BCMA Neutralizing Antibody, Mouse IgG1 (Clone: AM43, Cat. No. BCA-M43) captured on CM5 chip via anti-mouse antibodies surface can bind Human BCMA, His Tag (Cat. No. BCA-H522y) with an affinity constant of 0.388 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Idecabtagene vicleucel | bb-2121 | Approved | Bluebird Bio | Abecma | Japan | Multiple Myeloma | Bristol-Myers Squibb Kk | 2021-03-26 | Multiple Myeloma | Details |
| Belantamab mafodotin | GSK-2857916; GSK2857916 | Approved | Glaxosmithkline Plc | BLENREP | EU | Multiple Myeloma | Glaxosmithkline (Ireland) Ltd | 2020-08-05 | Multiple Myeloma | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Anti-BCMA CAR-NK Cell Therapy (Sichuan Kelun-Biotech) | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Multiple Myeloma | Details | |
| Anti-BCMA/CD19 CAR-T（Autolus） | Phase 1 Clinical | Multiple Myeloma | Details | ||
| BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Icell Gene Therapeutics | Multiple Myeloma | Details | |
| P-BCMA-101 | P-BCMA-101 | Phase 2 Clinical | Poseida Therapeutics | Multiple Myeloma | Details |
| LCAR-B4822M | LCAR-B4822M | Phase 1 Clinical | Genscript Biotech Corp | Multiple Myeloma | Details |
| Anti BCMA CART cell therapy (Shanghai YaKe Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma | Details | |
| MCM-998 | MCM-998; LXG-250 | Phase 1 Clinical | Novartis Pharma Ag | Multiple Myeloma | Details |
| KITE-585 | KITE-585 | Phase 1 Clinical | Kite Pharma, National Cancer Institute | Multiple Myeloma | Details |
| BCMA CAR-T Cells (Pregene) | PRG-1801 | Phase 1 Clinical | Shenzhen Prekin Biopharmaceutical Co Ltd | Multiple Myeloma | Details |
| CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University | Multiple Myeloma | Details | |
| BCMA Targeted CAR-T Cell Therapy (Yake Biotechnology) | CBG-002 CAR-T | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma | Details |
| Autologous BCMA-directed CAR T-cell therapy (The First Affiliated Hospital of Soochow University) | Phase 3 Clinical | The First Affiliated Hospital Of Soochow University | Multiple Myeloma | Details | |
| Anti-BCMA CAR-T cell therapy (Xinqiao Hospital) | Phase 1 Clinical | Multiple Myeloma | Details | ||
| SEA-BCMA | SEA-BCMA; SGN-BCMA | Phase 1 Clinical | Seattle Genetics | Multiple Myeloma | Details |
| PBCAR-269A | PBCAR-269A | Phase 2 Clinical | Precision Biosciences | Multiple Myeloma | Details |
| Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) | Phase 1 Clinical | Shengyan Pharmaceutical Technology | Multiple Myeloma | Details | |
| CXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Multiple Myeloma | Details | |
| HBI-0101 | HBI-0101 | Phase 1 Clinical | Hadassah Medical Organization | Details | |
| lentiviral transfected chimeric antigen receptor T-cells(Icell Gene) | Icell Gene Therapeutics | Details | |||
| C-CAR088 | C-CAR088 | Phase 1 Clinical | Cellular Biomedicine (Shanghai) Co Ltd | Multiple Myeloma | Details |
| CC-99712 | CC-99712 | Phase 1 Clinical | Celgene Corp | Multiple Myeloma | Details |
| MEDI-2228 | MEDI-2228 | Phase 1 Clinical | Medimmune Llc | Multiple Myeloma | Details |
| CC-98633 | CC-98633 | Phase 1 Clinical | Celgene Corp | Multiple Myeloma | Details |
| BCMA CAR-NK 92 cell therapy (Asclepius Technology Company Group) | Phase 2 Clinical | Asclepius Technology Company Group | Multiple Myeloma | Details | |
| Anti-BCMA CAR T cell therapy (Wuhan Bio-Raid Biotechnology) | Clinical | Wuhan Bio-Raid Biotechnology | Hematologic Neoplasms | Details | |
| BCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Icell Gene Therapeutics | Multiple Myeloma | Details | |
| ACTR 087/SEA BCMA combination therapy | Phase 1 Clinical | Unum Therapeutics | Multiple Myeloma | Details | |
| BCMA-UCART cell therapy (Shanghai Bioray Laboratory) | Bioray Laboraytories Inc | Details | |||
| GC-012F | GC-012F | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Multiple Myeloma | Details |
| JWCAR129 | JWCAR129; JWCAR-129 | Phase 1 Clinical | Suzhou Yaomingjunuo Biotechnology Co Ltd | Multiple Myeloma | Details |
| BCMA-targeted universal LCAR-BCX cell therapy (Nanjing Legend Biotech) | LCAR-BCX | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Multiple Myeloma | Details |
| BCMA CAR-T cell therapy (Hebei Senlang Biotechnology) | Clinical | Hebei Senlang Biological Technology Co Ltd | Multiple Myeloma | Details | |
| Anti-BCMA CAR-T cell therapy (PersonGen Biomedicine) | Phase 1 Clinical | Persongen Biotherapeutics | Multiple Myeloma | Details | |
| BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) | Phase 1 Clinical | The First Affiliated Hospital Of Nanchang University | Multiple Myeloma | Details | |
| Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology) | Clinical | Huazhong University Of Science And Technology | Multiple Myeloma | Details | |
| Anti BCMA chimeric antigen receptor T cell therapy (Chongqing Precision Biotech) | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Multiple Myeloma | Details | |
| Anti-BCMA chimeric antigen receptor T cell therapy (Cartesian) | Descartes-08 | Phase 2 Clinical | Cartesian Therapeutics | Myasthenia Gravis; Multiple Myeloma | Details |
| Anti-CD19+/BCMA CAR-T cells (Hrain Biotechnology) | Phase 1 Clinical | Hrain Biotechnology | POEMS Syndrome | Details | |
| Anti-BCMA CAR T-cell therapy (Arcellx) | CART-ddBCMA | Phase 1 Clinical | Arcellx | Multiple Myeloma | Details |
| BCMA CAR-T cell therapy (Chongqing Precision Biotech) | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Plasmacytoma; Multiple Myeloma; Neoplasms, Plasma Cell | Details | |
| Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology) | BCMA-CART | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Multiple Myeloma | Details |
| CTX-120 | CTX-120 | Phase 1 Clinical | Crispr Therapeutics | Multiple Myeloma | Details |
| Pacanalotamab | AMG-420; BI-836909 | Phase 1 Clinical | Micromet | Multiple Myeloma | Details |
| ALLO-605 | ALLO-605; ALLO605 | Phase 2 Clinical | Allogene Therapeutics Inc | Multiple Myeloma | Details |
| ALLO-715 | ALLO-715 | Phase 1 Clinical | Allogene Therapeutics Inc, Cellectis | Multiple Myeloma | Details |
| BCMA CAR-T Cell Therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Multiple Myeloma | Details | |
| AMG-224 | AMG-224 | Phase 1 Clinical | Amgen Inc | Multiple Myeloma | Details |
| EMB-06(Shanghai Epimab Biotherapeutics) | EMB-06; EMB06 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Multiple Myeloma | Details |
| BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) | Phase 2 Clinical | People'S Liberation Army General Hospital Military Service | Multiple Myeloma | Details | |
| Alnuctamab | CC-93269; EM-901 | Phase 1 Clinical | Celgene Corp | Multiple Myeloma | Details |
| CM-336(Connaught Biomedical Technology) | CM-336 | Phase 1 Clinical | Keymed Biosciences Co Ltd | Multiple Myeloma | Details |
| REGN-5459 | REGN-5459 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Multiple Myeloma; Renal Insufficiency, Chronic | Details |
| Orvacabtagene autoleucel | ET-140; FCARH-143; ET140-CAR; MCARH-171; JCARH-125 | Phase 2 Clinical | Juno Therapeutics | Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
| PHE-885 | PHE-885 | Phase 2 Clinical | Novartis Pharma Ag | Hematologic Neoplasms; Multiple Myeloma | Details |
| GR-1803 | GR-1803 | Phase 1 Clinical | Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd | Multiple Myeloma | Details |
| BCMA-NKE | BCMA-NKE | Phase 1 Clinical | Bristol-Myers Squibb Company | Multiple Myeloma | Details |
| Zevorcabtagene Autoleucel | CT-053-CARsgen | Phase 2 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Multiple Myeloma | Details |
| bb-21217 | bb-21217 | Phase 1 Clinical | Bristol-Myers Squibb Company, Bluebird Bio | Multiple Myeloma | Details |
| TNB-383B | TNB-383B; ABBV-383 | Phase 1 Clinical | Teneobio, Abbvie Inc | Multiple Myeloma | Details |
| BCMA TriTAC | HPN-217 | Phase 2 Clinical | Harpoon Therapeutics, Abbvie Inc | Multiple Myeloma | Details |
| Human BCMA chimeric antigen receptor autologous T cell（Nanjing Reindeer Medical Technology） | CT-103A; CT103A; IBI-326 | Phase 3 Clinical | Innovent Biologics(Suzhou) Co Ltd, Nanjing Iaso Biotherapeutics Co Ltd | Multiple Myeloma; Neuromyelitis Optica | Details |
| Recombinant humanized anti-BCMA/CD3 bispecific antibody(New Time Pharmaceutical) | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Multiple Myeloma | Details | |
| Pavurutamab | AMG-701 | Phase 1 Clinical | Amgen Inc | Multiple Myeloma | Details |
| Elranatamab | PF-06863135 | Phase 3 Clinical | Pfizer Pharmaceuticals Ltd (China) | Bone Marrow Neoplasms; Multiple Myeloma | Details |
| Humanized CART Directed Against BCMA | ARI-0002h | Instituto De Salud Carlos Iii | Details | ||
| FT-576 | FT-576 | Phase 1 Clinical | University Of Minnesota, Fate Therapeutics Inc | Bone Marrow Neoplasms; Multiple Myeloma | Details |
This web search service is supported by Google Inc.
A-Z
FLAG
Star Staining
ViruStop
Aneuro
ComboX
ActiveMax
GENPower
